Gulf Today, 24 February 2026: The UAE has activated a first‑of‑its‑kind mechanism requiring pharmaceutical companies to appoint multiple agents for each medical product to break long‑standing monopolies and strengthen national pharmaceutical security.

The Emirates Drug Establishment (EDE) said it has activated the new mechanism under Federal Decree‑Law No. 38/2024 on Medical Products, the Pharmacy Profession, and Pharmaceutical Establishments, marking the first time the UAE has obliged pharmaceutical firms to register more than one authorised agent per medical product. The move is part of a national strategy to enhance pharmaceutical security, diversify supply chains, and ensure the continuous availability of medicines and medical products across the country.

Officials explained that the reform aims to end exclusive‑agent control, reduce the risk of supply disruptions during emergencies or operational challenges, and improve the efficiency and resilience of medical‑product distribution. The EDE added that expanding the number of authorised agents will accelerate delivery times, improve inventory management, and boost the UAE’s attractiveness as an investment destination in the pharmaceutical sector.

For more news and content, try Lexis Middle East. Click on lexis.ae/demo to begin your free trial of Lexis® Middle East platform.

You can also explore the legal landscape by subscribing to our Weekly Newsletter.

Want to learn more about Lexis® Middle East? Visit https://www.lexis.ae/lexis-middle-east-law/.